Deerfield Management Company, L.P. (Series C) Puma Biotechnology, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$6.63 - $9.39 $25 Million - $35.4 Million	-3,769,795 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$9.38 - $13.63 $1.78 Million - $2.59 Million	-189,946 Reduced 4.8%	3,769,795 $36.6 Million
Q4 2020 Feb 16, 2021	BUY	$7.78 - $12.13 $8.82 Million - $13.7 Million	1,133,414 Added 40.1%	3,959,741 $40.6 Million
Q3 2020 Nov 16, 2020	BUY	$9.5 - $11.14 $26.9 Million - $31.5 Million	2,826,327 New	2,826,327 $28.5 Million
Q2 2020 Aug 14, 2020	SELL	$7.01 - $13.24 $6.75 Million - $12.8 Million	-963,212 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$6.28 - $14.57 $3.56 Million - $8.26 Million	566,740 Added 142.95%	963,212 $8.13 Million
Q4 2019 Feb 14, 2020	BUY	$6.5 - $10.73 $2.58 Million - $4.25 Million	396,472 New	396,472 $3.47 Million

Others Institutions Holding PBYI

# of Institutions

101

Shares Held

29M

Call Options Held

50.6K

Put Options Held

16.3K

Vanguard Group Inc Valley Forge, PA

3.64M
Shares

$10.7 Million
0.0% of portfolio
Black Rock Inc. New York, NY

3.57M
Shares

$10.5 Million
0.0% of portfolio
Frazier Life Sciences Management, L.P. Menlo Park, CA

3.06M
Shares

$9 Million
0.42% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

2.88M
Shares

$8.47 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

1.97M
Shares

$5.79 Million
0.02% of portfolio

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $134M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account